Endometriosis Australia welcomes commitment to ongoing access to Zoladex

Endometriosis Australia welcomes confirmation that Zoladex® (goserelin 3.6 mg) will remain available to Australian patients who rely on it, following AstraZeneca’s decision to supply the medication free of charge and indefinitely for people who have no other suitable treatment option. 

When the withdrawal was first announced, Endometriosis Australia raised serious concerns about what the loss of an established treatment would mean for thousands of Australian women living with endometriosis and adenomyosis, and for the many others who depend on this medication, including people living with breast cancer. The response that followed, from patients, clinicians, advocates and organisations across the country, made the strength of that concern impossible to ignore. 

“This outcome shows what is possible when the voices of people living with endometriosis are heard. Access to an established treatment should never be something women have to fight to keep, and we are relieved this medication will remain available to those who need it.”

— A/Prof. Anusch Yazdani, Endometriosis Australia Medical Director

It is important to be clear about what this means in practice. From 1 November 2026, the Zoladex 3.6 mg monthly implant will no longer be available through the Pharmaceutical Benefits Scheme or usual pharmacy channels. Instead, it will be supplied at no cost through AstraZeneca’s Zoladex Continuity Program for patients without another suitable treatment option. This applies both to people already receiving the implant and to those who may need to begin treatment after that date. 

Women currently receiving treatment should not stop therapy or change their management without first discussing their individual circumstances with their treating specialist. Anyone who relies on the implant is encouraged to stay in contact with their prescribing clinician, who will be able to guide enrolment in the program. AstraZeneca has advised that full details on how to enrol will be available in September 2026. 

While this is a welcome outcome, Endometriosis Australia remains mindful that reliable, long-term access is what matters most to the community. Endometriosis Australia will continue to monitor the situation closely, advocate for patients, and work with clinicians and policymakers to ensure that no one who depends on this treatment is left without it.